Form 4: Royalty Pharma CFO Sells Shares Under 10b5-1 Plan

Royalty Pharma plc's EVP & CFO, Terrance P. Coyne, sold over 34,000 Class A Ordinary Shares for approximately $45.32 per share as part of a pre-arranged trading plan.

Summary

• Terrance P. Coyne, EVP & CFO of Royalty Pharma plc, sold a total of 34,791 Class A Ordinary Shares.
• The sales occurred on February 23, 2026, at a weighted average price of $45.3165 per share, with prices ranging from $44.97 to $45.60.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on August 8, 2025.
• Following these transactions, Mr. Coyne beneficially owns 229,690 Class A Ordinary Shares directly and indirectly.
• Additionally, Mr. Coyne and family vehicles hold limited partnership interests exchangeable into 6,448,180 Class A Ordinary Shares and Class E Ordinary Shares of Royalty Pharma Holdings Ltd exchangeable into 1,807,277 Class A Ordinary Shares, subject to vesting.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction under a pre-arranged 10b5-1 plan, which mitigates concerns typically associated with insider sales. The EVP & CFO retains substantial beneficial ownership, indicating continued alignment with shareholder interests.

Positives

• The sale was conducted under a pre-arranged 10b5-1 plan, indicating it was not based on new, non-public information.
• Mr. Coyne retains significant beneficial ownership in Royalty Pharma plc, including direct shares, indirect holdings, and exchangeable interests totaling over 8.2 million shares.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces the insider's direct equity stake.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the inherent market perception of insider sales.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing, which primarily reports an insider transaction.

Industry Context

StockSavvy.ai notes that insider sales, particularly by high-ranking executives like an EVP & CFO, are routinely monitored by investors for signals about management's confidence in the company's future. However, sales executed under a Rule 10b5-1 plan, as in this case, are generally viewed as less indicative of a change in sentiment because they are pre-scheduled and not based on immediate, non-public information. Royalty Pharma operates in the specialized pharmaceutical royalty acquisition sector, where long-term asset value and pipeline strength are key drivers, making executive holdings a significant indicator of alignment with shareholder interests.

Comparison to Industry Standards

• StockSavvy.ai observes that insider trading activity is a common occurrence across all industries.
• For pharmaceutical and biotech companies, insider transactions are often scrutinized for insights into drug development milestones or regulatory approvals.
• While no direct comparable companies or projects are mentioned in this filing, the execution of a 10b5-1 plan aligns with best practices for corporate insiders to manage their personal finances while mitigating concerns about trading on material non-public information, a standard widely adopted by executives in publicly traded companies like Pfizer, Johnson & Johnson, or Merck.

Related Party Transactions

• Indirect beneficial ownership through family vehicles and LLCs are part of the reporting person's holdings.

Stakeholder Impact

• Shareholders: May observe a slight reduction in direct insider ownership, but the 10b5-1 plan context and significant remaining holdings should temper any negative sentiment.
• Employees, Customers, Suppliers, Creditors: No direct impact is indicated by this insider transaction report.

Key Dates

Recommendation

The insider sale by the EVP & CFO, while a reduction in direct holdings, was executed under a pre-arranged 10b5-1 plan, which typically signals a planned financial management activity rather than a reaction to new, negative company-specific information. Furthermore, the executive retains substantial beneficial ownership in the company, indicating continued long-term alignment. Therefore, this transaction alone does not warrant a change in investment thesis, and a 'hold' recommendation is appropriate.

Keywords

Royalty Pharma, RPRX, Insider Trading, Form 4, Terrance P. Coyne, EVP & CFO, Share Sale, 10b5-1 Plan, Beneficial Ownership, Pharmaceutical Royalties